Charlottesville’s ZielBio finalized a $15 million funding round this summer to complete initial trials of a cancer treatment drug it hopes to bring to market in 2024. The genesis for the company ...
No significant financial relationships to disclose. This is an ASCO Meeting Abstract from the 2009 ASCO Annual Meeting I. This abstract does not include a full text component.
Circulating tumor cell detection: A direct comparison between the CellSearch System, the AdnaTest, and CK-19/mammaglobin RT-PCR in patients with metastatic breast cancer ...
ZB131 is a first-in-class humanized monoclonal antibody targeting cancer-specific plectin (CSP), which is expressed on the surface of cancer cells in many solid tumors New, preclinical research ...
Medical researchers have discovered a new biomarker in cancer stem cells that govern cancer survival and spread, and it's raising hope that drug discovery to kill cancer stem cells could follow suit.
In the world of cancer biology, not all biomarkers are created equal. These molecules that alert doctors that an abnormal process may be underway can appear as an array of aberrant proteins, such as ...
In the world of cancer biology, not all biomarkers are created equal. These molecules that alert doctors that an abnormal process may be underway can appear as an array of aberrant proteins, such as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results